Enwei Pharmaceutical Co

Enwei Pharmaceutical Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enwei Pharmaceutical Co (301331.SZ) as of Oct 27, 2026 is 61.13 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 79.48 M CNY — a change of -23.08% (lower).

EBITDA

61.13 MCNY

YoY

-23.08%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enwei Pharmaceutical Co is 2025 61.13 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enwei Pharmaceutical Co was 2024 79.48 M CNY. It decreases by -23.08% lower compared to the previous year.

The Enwei Pharmaceutical Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
134.21 M CNY
Jan 1, 2020
143.72 M CNY
Jan 1, 2021
136.23 M CNY
Jan 1, 2022
97.30 M CNY
Jan 1, 2023
111.08 M CNY
Jan 1, 2024
79.48 M CNY
Jan 1, 2025
61.13 M CNY
The Enwei Pharmaceutical Co EBITDA history
YEAREBITDAYoY
61.13 MCNY-23.08%
79.48 MCNY-28.45%
111.08 MCNY+14.16%
97.30 MCNY-28.58%
136.23 MCNY-5.21%
143.72 MCNY+7.09%
134.21 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enwei Pharmaceutical Co is 61.13 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enwei Pharmaceutical Co changed from 79.48 M CNY to 61.13 M CNY, representing a -23.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Enwei Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co